Literature DB >> 32035626

Risk factors for posttreatment recurrence in patients with intermediate-risk papillary thyroid carcinoma.

Yonghan Kim1, Jong-Lyel Roh2, Dong Eun Song3, Kyung-Ja Cho3, Seung-Ho Choi1, Soon Yuhl Nam1, Sang Yoon Kim1.   

Abstract

BACKGROUND: Papillary thyroid carcinoma (PTC) is generally associated with favorable outcomes; however, intermediate-risk requires further evaluation. We therefore examined risk factors for posttreatment recurrence in patients with intermediate-risk PTC.
METHODS: This study involved 1782 patients who underwent thyroidectomy for intermediate-risk PTC. Univariate and multivariate Cox proportional hazard regression analyses were used to identify the significant factors predictive of posttreatment recurrence-free survival (RFS).
RESULTS: Of intermediate-risk factors, univariate analyses showed that clinical and pathological cervical lymph node (LN) positivity (cN1 and pN1), aggressive histology, and multifocality with microscopic extrathyroidal extension were significantly associated with RFS outcomes (all P < 0.05). In multivariate analyses, cN1, >5 pN1, and posttreatment radioactive iodine (RAI)-avid metastatic foci of intermediate risk remained the independent factors predictive of RFS (all P < 0.05). The combination of any three or more of these intermediate-risk factors appeared to increase the posttreatment recurrence rate.
CONCLUSION: Clinical nodal positivity, the number of positive LNs, and the presence of RAI-avid metastatic foci in the ATA intermediate-risk category might independently decrease RFS in patients with intermediate-risk PTC.
Copyright © 2020 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Cervical lymph node; Intermediate risk; Papillary thyroid carcinoma; Predictive factors; Recurrence

Year:  2020        PMID: 32035626     DOI: 10.1016/j.amjsurg.2020.01.049

Source DB:  PubMed          Journal:  Am J Surg        ISSN: 0002-9610            Impact factor:   2.565


  1 in total

1.  Papillary thyroid carcinoma tall cell variant shares accumulation of mitochondria, mitochondrial DNA mutations, and loss of oxidative phosphorylation complex I integrity with oncocytic tumors.

Authors:  Oleksiy Tsybrovskyy; Monica De Luise; Dario de Biase; Leonardo Caporali; Claudio Fiorini; Giuseppe Gasparre; Valerio Carelli; Dominik Hackl; Larisa Imamovic; Silke Haim; Manuel Sobrinho-Simões; Giovanni Tallini
Journal:  J Pathol Clin Res       Date:  2021-11-17
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.